{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:18Z","timestamp":1793773818730,"version":"4.6.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the absence of head-to-head trials, an indirect-treatment comparison can estimate the treatment effect of tisagenlecleucel in comparison with blinatumomab on rates of complete remission (CR) and overall survival (OS) in patients with relapsed or primary refractory (R\/R) acute lymphoblastic leukemia (ALL). Patient-level data from two pivotal trials, ELIANA (tisagenlecleucel; n = 79) and MT103-205 (blinatumomab; n = 70), were used in comparisons of CR and OS, controlling for cross-trial difference in available patient characteristics. Five different adjustment approaches were implemented: stabilized inverse probability of treatment weight (sIPTW); trimmed sIPTW; stratification by propensity score quintiles; adjustment for prognostic factors; and adjustment for both prognostic factors and propensity score. Comparative analyses indicate that treatment with tisagenlecleucel was associated with a statistically significant higher likelihood of achieving CR and lower hazard of death than treatment with blinatumomab. The tisagenlecleucel group exhibited a higher likelihood of CR than the blinatumomab group in every analysis regardless of adjustment approach (odds ratios: 6.71-9.76). Tisagenlecleucel was also associated with a lower hazard of death than blinatumomab in every analysis, ranging from 68% to 74% lower hazard of death than with blinatumomab, determined using multiple adjustment approaches (hazard ratios: 0.26-0.32). These findings support the growing body of clinical trials and real-world evidence demonstrating that tisagenlecleucel is an important treatment option for children and young adults with R\/R ALL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020004045","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:09:30Z","timestamp":1633118970000},"page":"5387-5395","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed\/refractory acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-5917","authenticated-orcid":false,"given":"Michael R.","family":"Verneris","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus (CU Anschutz), Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus (CU Anschutz), Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt, LTD, Hyderabad, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Li","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-8418","authenticated-orcid":false,"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7803-2366","authenticated-orcid":false,"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"issue":"1","key":"2021120916264135000_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"2021120916264135000_B2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Brown","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"issue":"5","key":"2021120916264135000_B3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021120916264135000_B4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021120916264135000_B5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"2021120916264135000_B6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med."},{"issue":"8","key":"2021120916264135000_B7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"2021120916264135000_B8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"issue":"9","key":"2021120916264135000_B9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy."},{"issue":"7655","key":"2021120916264135000_B10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature."},{"issue":"12","key":"2021120916264135000_B11","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood."},{"issue":"12","key":"2021120916264135000_B12","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021120916264135000_B13","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood."},{"issue":"1","key":"2021120916264135000_B14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021120916264135000_B15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0895-4356(01)00414-0","article-title":"A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis","volume":"55","author":"Lambert","year":"2002","journal-title":"J Clin Epidemiol."},{"issue":"6","key":"2021120916264135000_B16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health."},{"key":"2021120916264135000_B17","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume-title":"Blood","author":"Grupp","year":"2018"},{"issue":"5","key":"2021120916264135000_B18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"36","key":"2021120916264135000_B19","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021120916264135000_B20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J."},{"issue":"12","key":"2021120916264135000_B21","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","article-title":"Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study","volume":"111","author":"Mody","year":"2008","journal-title":"Blood."},{"issue":"4","key":"2021120916264135000_B22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2354.2008.00954.x","article-title":"Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning","volume":"18","author":"Reinfjell","year":"2009","journal-title":"Eur J Cancer Care (Engl)."},{"issue":"12","key":"2021120916264135000_B23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/cer-2020-0069","article-title":"Tisagenlecleucel versus historical standard therapies for pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"9","author":"Ma","year":"2020","journal-title":"J Comp Eff Res."},{"key":"2021120916264135000_B24","article-title":"Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory children and young adults with acute lymphoblastic leukemia (ALL): real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry","volume-title":"Blood","author":"Grupp","year":"2019"},{"issue":"7","key":"2021120916264135000_B25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J."},{"key":"2021120916264135000_B26","author":"Locatelli","year":"2020"},{"key":"2021120916264135000_B27","author":"Locatelli","year":"2020"},{"key":"2021120916264135000_B28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-137576","article-title":"Efficacy and safety of blinatumomab for relapsed or refractory pediatric ALL patients: a systematic review","volume":"136","author":"Khan","year":"2020","journal-title":"Blood."},{"key":"2021120916264135000_B29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-140242","article-title":"Predictive model of response to blinatumomab therapy in children and adults with relapsed\/refractory B-ALL","volume":"136","author":"Markova","year":"2020","journal-title":"Blood."},{"issue":"9","key":"2021120916264135000_B30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4155\/cli.13.71","article-title":"Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia","volume":"3","author":"Devidas","year":"2013","journal-title":"Clin Investig (Lond)."},{"key":"2021120916264135000_B31","first-page":"5","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clin Pharmacol."},{"issue":"5","key":"2021120916264135000_B32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"13","key":"2021120916264135000_B33","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/bloodadvances.2018025726","article-title":"Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv."},{"key":"2021120916264135000_B34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5387\/1850206\/advancesadv2020004045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5387\/1850206\/advancesadv2020004045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T16:32:41Z","timestamp":1639067561000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/5387\/477129\/Indirect-comparison-of-tisagenlecleucel-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":34,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004045","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}